stockrowANI Pharmaceuticals, Inc. (ANIP) vs BioCryst Pharmaceuticals, Inc. (BCRX)
- ANI Pharmaceuticals, Inc. ANIP 69.03 −3.66%
- BioCryst Pharmaceuticals, Inc. BCRX 7.55 −8.37%
ANI Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. BioCryst Pharmaceuticals, Inc. is the larger, with a market value of $2.0B against $1.6B — 1.2× the size. BioCryst Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; ANI Pharmaceuticals, Inc. trades at 13.3×. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 60.3% against 25.9%. ANI Pharmaceuticals, Inc. has the higher net margin (11.2% vs −37.4%) and the higher return on invested capital (46.4% vs 0.00%). Across the 18 metrics below, ANI Pharmaceuticals, Inc. leads on 9 and BioCryst Pharmaceuticals, Inc. on 9.
Valuation
Profitability
| Metric | ANIP | BCRX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 61.06% | 97.89% | 53.51% |
| Operating margin | 15.99% | (30.10%) | 0.00% |
| Net margin | 11.22% | (37.41%) | (2.45%) |
| Free cash flow margin | 19.72% | 38.11% | 0.00% |
| Return on equity | 20.45% | 91.60% | (0.80%) |
| Return on assets | 7.85% | (69.33%) | (1.67%) |
| Return on invested capital | 46.43% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack